Nefiracetam

Nefiracetam is a Piracetam derivative made by Daiichi in Japan, carrying a 2,6-dimethylphenyl group on the acetamide nitrogen. It was developed for Alzheimer-type and post-stroke vascular dementia [1].

It did not get there. The 2010 survey of the piracetam family places nefiracetam in the subgroup of derivatives with unestablished clinical efficacy and records flatly that it failed to improve cognition in post-stroke patients [6]. What did get properly tested, in three randomized trials run by Robinson and colleagues, was something else entirely: mood and motivation after stroke.

The structural change is bigger than it sounds. Hanging a bulky, lipophilic 2,6-dimethylphenyl group off the acetamide nitrogen turns the small, polar, highly water-soluble piracetam molecule into something quite different — and the pharmacology changes with it. Where piracetam needs millimolar concentrations to shift membrane fluidity, nefiracetam potentiates receptors at 1 nanomolar [1].

What the research found. The preclinical record is the strongest of any racetam. Nefiracetam reversed amnesia induced by scopolamine, bicuculline, picrotoxin, ethanol, chlordiazepoxide, cycloheximide and carbon monoxide, and improved learning in rats with excitotoxic or thermal lesions of the basal forebrain cholinergic system — all with bell-shaped dose-response curves in both the behavioral and the biochemical measures [7]. The human record is the opposite: the cognition program failed and is recorded only in a review [6]; the 159-patient depression trial missed its primary endpoint [3]; a post-hoc apathy signal at 900 mg a day was positive [4]; and the trial meant to confirm it screened 2514 patients and randomized 13 [5].

Nefiracetam is the racetam with the most precisely worked-out mechanism, and it operates at concentrations three to six orders of magnitude below the others.

At 1 nM it potentiates α4β2 nicotinic acetylcholine receptor currents in rat cortical neurons to 200–300% of control, while barely touching α7. The dose-response is bell-shaped: 10 µM does less than 1 nM. Protein kinase A and C inhibitors do not block it and pertussis toxin does not either, but cholera toxin abolishes it — so the effect runs through Gs proteins [1]. (Aniracetam does the same thing at 0.1 nM in the same preparation.)

Here, “target” means a receptor whose function changes in electrophysiology, not a mapped ligand-binding site. The cholera-toxin sensitivity places the α4β2 effect upstream in Gs signaling, while the NMDA effect below is mediated by PKCα-dependent phosphorylation. The cited experiments establish receptor modulation but not orthosteric agonism [1][2].

Separately, nefiracetam potentiates NMDA receptor currents. This one is PKC-dependent: it activates PKCα with a bell-shaped curve peaking at 10 nM, increases phosphorylation of the NMDA receptor, allosterically enhances glycine binding, and largely eliminates the voltage-dependent magnesium block [2].

Both converge on plasticity. At 1–1000 nM nefiracetam increases fEPSP slope in rat hippocampal CA1 and enhances long-term potentiation, with the same bell-shaped 10 nM peak, through CaMKII and PKCα and AMPA receptor phosphorylation [8]. Presynaptic nicotinic receptors are the functional target for a long-lasting facilitation of hippocampal neurotransmission [9].

Calcium channels are the third leg. In NG108-15 cells, 1 µM nefiracetam enhanced the activity of high-voltage- activated N- and L-type calcium channels and left T-type channels alone. Dibutyryl cAMP reproduced the effect and pertussis toxin blocked it, so this arm runs through PTX-sensitive G proteins and a cAMP-dependent pathway — the opposite G-protein sensitivity from the α4β2 effect, which cholera toxin blocks [1][10]. That is not a contradiction so much as evidence that nefiracetam is doing several separable things.

The calcium-channel arm is load-bearing for behavior. Nefiracetam's reversal of scopolamine-induced amnesia was abolished by the L-type blockers nifedipine and flunarizine, but not by diltiazem [7]. Enhanced calcium entry at the terminal is the most economical explanation for why the drug raises release of several transmitters at once.

The same nicotinic receptor, two opposite effects, depending on concentration. On Torpedo nicotinic receptors expressed in Xenopus oocytes, 0.01–0.1 µM nefiracetam produced a short-term depression of acetylcholine-evoked currents, mediated by PTX-sensitive G-protein activation of protein kinase A and phosphorylation of the receptor. At 1–10 µM the same drug produced a long-term enhancement, mediated by calcium-dependent protein kinase C phosphorylating the same receptor [10]. Whichever kinase gets to the receptor decides the sign of the effect.

GABA: turnover, not receptors. Nefiracetam is formally a cyclic GABA derivative, and it does change GABAergic function — but not by binding anything. Across the entire range from 10⁻¹⁰ to 10⁻³ M it did not affect GABAA or benzodiazepine receptor binding in rat brain. What it did was presynaptic and metabolic: 10 mg/kg orally for seven days raised GABA turnover and glutamic acid decarboxylase activity in cortex and hippocampus and stimulated sodium-dependent high-affinity GABA uptake in cortical synaptosomes, while 1–10 nM markedly increased potassium-evoked GABA release from cortical slices [11]. Consistent with that, nefiracetam reversed amnesia caused by the GABAA blockers bicuculline and picrotoxin, and those same drugs antagonized its anti-amnesic effect [7][12].

Cholinergic effects beyond the nicotinic receptor. Nefiracetam stimulated acetylcholine release in the frontal cortex, and repeated administration raised choline acetyltransferase activity and improved learning in rats whose basal forebrain cholinergic neurons had been destroyed by excitotoxin or thermal lesion. It also corrected cholinergic and monoaminergic transmitter changes in AF64A-lesioned animals, and reversed amnesia induced by scopolamine, ethanol, chlordiazepoxide, cycloheximide and carbon monoxide [7]. In the cycloheximide model, nefiracetam not only blocked the drug-induced loss of GABAA and muscarinic binding sites but raised muscarinic sites above control [12].

The bell-shaped curves matter. They appear in the α4β2 potentiation, the PKCα activation, the LTP enhancement, the GABA release and the behavioral tests [1][2][7][8][11]. More is not better for this compound, and the human trials used gram-scale oral doses.

The cited trials report no safety problems at 600–900 mg a day in stroke patients over 4 to 12 weeks [3][4][5], but none of them was designed as a safety study and none reports an adverse-event table in the material available here. There is no approved product and therefore no prescribing information.

The honest summary is that nefiracetam has been given to a few hundred people in short trials without anything alarming being reported, and that this is a long way from an established safety profile.